Cargando…

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

OBJECTIVES: : Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices. Using data on exports of raw materials in 2015, we calculated currently feasible generic prices...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew, Simmons, Bryony, Gotham, Dzintars, Fortunak, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946692/
https://www.ncbi.nlm.nih.gov/pubmed/27482432
_version_ 1782443058286034944
author Hill, Andrew
Simmons, Bryony
Gotham, Dzintars
Fortunak, Joseph
author_facet Hill, Andrew
Simmons, Bryony
Gotham, Dzintars
Fortunak, Joseph
author_sort Hill, Andrew
collection PubMed
description OBJECTIVES: : Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices. Using data on exports of raw materials in 2015, we calculated currently feasible generic prices of sofosbuvir and daclatasvir. METHODS: : Data on per-kilogram prices of sofosbuvir and daclatasvir active pharmaceutical ingredients (API) exported from India were extracted from an online database. To the cost of the amount of API needed for a 12-week treatment course, we added cost estimates for formulation (40%), packaging (US$0.35/month), and a mark-up (50%). RESULTS: : Between 1 January and 15 October 2015, over 5 tons of sofosbuvir were exported, with prices decreasing by US$702/kg/month, and observed prices of US$2501/kg in early September. Over the same period, 84 kg of daclatasvir were exported, with prices decreasing by US$1664/kg/month to US$1897/kg. Using the price estimation algorithm, we estimated the price of a generic sofosbuvir–daclatasvir combination regimen at US$200 per patient for a 12-week treatment course. CONCLUSION: : The costs of generic production of sofosbuvir and daclatasvir are rapidly decreasing. Sofosbuvir–daclatasvir combination treatment could be produced for US$200 per patient per 12-week course.
format Online
Article
Text
id pubmed-4946692
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Mediscript Ltd
record_format MEDLINE/PubMed
spelling pubmed-49466922016-08-01 Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C Hill, Andrew Simmons, Bryony Gotham, Dzintars Fortunak, Joseph J Virus Erad Original Research OBJECTIVES: : Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices. Using data on exports of raw materials in 2015, we calculated currently feasible generic prices of sofosbuvir and daclatasvir. METHODS: : Data on per-kilogram prices of sofosbuvir and daclatasvir active pharmaceutical ingredients (API) exported from India were extracted from an online database. To the cost of the amount of API needed for a 12-week treatment course, we added cost estimates for formulation (40%), packaging (US$0.35/month), and a mark-up (50%). RESULTS: : Between 1 January and 15 October 2015, over 5 tons of sofosbuvir were exported, with prices decreasing by US$702/kg/month, and observed prices of US$2501/kg in early September. Over the same period, 84 kg of daclatasvir were exported, with prices decreasing by US$1664/kg/month to US$1897/kg. Using the price estimation algorithm, we estimated the price of a generic sofosbuvir–daclatasvir combination regimen at US$200 per patient for a 12-week treatment course. CONCLUSION: : The costs of generic production of sofosbuvir and daclatasvir are rapidly decreasing. Sofosbuvir–daclatasvir combination treatment could be produced for US$200 per patient per 12-week course. Mediscript Ltd 2016-01-01 /pmc/articles/PMC4946692/ /pubmed/27482432 Text en © 2016 The Authors. Journal of Virus Eradication published by Mediscript Ltd http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article published under the terms of a Creative Commons License.
spellingShingle Original Research
Hill, Andrew
Simmons, Bryony
Gotham, Dzintars
Fortunak, Joseph
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
title Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
title_full Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
title_fullStr Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
title_full_unstemmed Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
title_short Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
title_sort rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis c
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946692/
https://www.ncbi.nlm.nih.gov/pubmed/27482432
work_keys_str_mv AT hillandrew rapidreductionsinpricesforgenericsofosbuviranddaclatasvirtotreathepatitisc
AT simmonsbryony rapidreductionsinpricesforgenericsofosbuviranddaclatasvirtotreathepatitisc
AT gothamdzintars rapidreductionsinpricesforgenericsofosbuviranddaclatasvirtotreathepatitisc
AT fortunakjoseph rapidreductionsinpricesforgenericsofosbuviranddaclatasvirtotreathepatitisc